Table 2.

The incidence of adverse events in any grade or grade ≥3 for patients with R/R B-NHL.

AEs	Treatment	Any grade					Grade ≥3
		Included study	Event	Total patients	Pooled rate(95% Cl)	p-value	Included study	Event	Total patients	Pooled rate(95% Cl)	p-value
Hematological
Neutropenia	Copanlisib	3	59	242	0.2278[0.1297;0.3440]	P=0.2661	2	42	209	0.1801[0.0782;0.3124]	P=0.1811
	Including copanlisib plus rituximab	2	66	328	0.1067[0.0043;0.3190]		2	50	328	0.0936[0.0067;0.2645]
	Overall	5	125	570	0.1899[0.1202;0.2711]		4	92	537	0.1475[0.0843;0.2246]
Decreased platelet count	Copanlisib	3	27	188	0.1436[0.0973;0.1972]	P=0.7445	2	7	155	0.0435[0.0100;0.0769]	P=0.5806
	Including copanlisib plus rituximab	2	52	328	0.3887[0.0770;0.7655]		2	10	328	0.0440[0.0000;0.1109]
	Overall	5	79	516	0.2101[0.1249;0.3105]		4	17	483	0.0281[0.0132;0.0429]
Non-hematological
Fatigue	Copanlisib	4	75	251	0.3276[0.2354;0.4557]	P<0.0001	2	4	209	0.0190[0.0050;0.0419]	P=0.2762
	Including copanlisib plus rituximab	2	52	328	0.2828[0.1143;0.6994]		2	5	328	0.0143[0.0043;0.0299]
	Overall	6	127	579	0.3033[0.2038;0.4513]		4	9	537	0.0160[0.0072;0.0284]
Diarrhea	Copanlisib	5	95	264	0.3594[0.3015;0.4172]	P=0.7627	3	13	222	0.0289[0.0001;0.1058]	P=0.8811
	Including copanlisib plus rituximab	2	113	328	0.3437[0.2925;0.3949]		2	17	328	0.0514[0.0302;0.0779]
	Overall	7	208	592	0.3506[0.3122;0.3889]		5	30	550	0.0509[0.0341;0.0708]
Nausea	Copanlisib	4	71	251	0.3580[0.2117;0.5042]	P=0.3357	2	2	209	0.0086[0.0000;0.0284]	P=0.6445
	Including copanlisib plus rituximab	2	80	328	0.4053[0.1214;0.6892]		2	2	328	0.0000[0.0000;0.0019]
	Overall	6	151	579	0.3498[0.2505;0.4491]		4	4	537	0.0000[0.0000;0.0053]
Pneumonia	Copanlisib	2	25	175	0.1403[0.0912;0.1972]	P=0.9685	1	12	142	0.1056	_
	Including copanlisib plus rituximab	2	45	328	0.1175[0.0806;0.1590]		2	21	328	0.0610[0.0352;0.0869]
	Overall	4	70	503	0.1261[0.0959;0.1591]		3	33	470	0.0703[0.0472;0.0933]
Hyperglycemia	Copanlisib	5	136	264	0.6369[0.4379;0.9264]	P<0.0001	4	87	231	0.3761[0.3148;0.4394]	P<0.0001
	Including copanlisib plus rituximab	2	228	328	0.6993[0.6513;0.7508]		2	185	328	0.5641[0.5101;0.6173]
	Overall	7	364	592	0.6675[0.5399;0.8254]		6	272	559	0.4514[0.5101;0.6173]
Hypertension	Copanlisib	5	106	264	0.4969[0.3045;0.6898]	P=0.0368	4	66	231	0.2757[0.2168;0.3384]	P=0.0074
	Including copanlisib plus rituximab	2	161	328	0.4789[0.2664;0.6950]		2	131	328	0.3934[0.3380;0.4502]
	Overall	7	267	592	0.4857[0.3604;0.6118]		6	197	559	0.3507[0.2576;0.4492]